Grünenthal Acquires US-company Valinor Pharma and Becomes Global Owner of Movantik
Grünenthal Acquires US-company Valinor Pharma and Becomes Global Owner of Movantik
- Grünenthal acquires the pharmaceutical company Valinor Pharma, further strengthening Grünenthal's footprint in the United States.
- With the acquisition, Grünenthal becomes the global owner of Movantik / Moventig (naloxegol).
- Since 2017, Grünenthal has invested more than €2 billion in successful M&A transactions, significantly strengthening its profitability.
- Grunenthal收购了药品公司Valinor Pharma，进一步加强了Grunenthal在美国的影响力。
- 通过此次收购，Grunenthal成为Movantik / Moventig (naloxegol)的全球拥有者。
- 自2017年以来，Grunenthal在成功的并购交易中投资超过20亿欧元，显著增强了其盈利能力。
AACHEN, Germany, July 22, 2024 /PRNewswire/ -- Grünenthal today announced the acquisition of US-based Valinor Pharma, LLC ("Valinor") and its product Movantik (naloxegol), with a total deal value of approx. $250 million inclusive of all royalty obligations. Grünenthal will finance the transaction using available liquidity.
德国亚琛，2024年7月22日 / PRNewswire——Grunenthal今天宣布收购总部位于美国的Valinor Pharma，LLC（“Valinor”）及其产品Movantik（naloxegol），包括所有版税义务在内的总交易价值约为2500万美元。Grunenthal将利用可用流动性进行交易。
Movantik is indicated for the oral treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. The transaction further expands Grünenthal's portfolio of established medicines and adds to the company's growing U.S. business. Gross sales from Movantik in the United States reached over $200 million in 2023.
Movantik用于口服治疗慢性非癌症疼痛成人患者的阿片样便秘（OIC）。此次交易进一步扩大了Grunenthal的成熟药物组合，并增加了该公司在增长的美国业务中的投入。Movantik在美国的总销售额在2023年达到了超过2亿美元。
"As a pain specialist, Movantik is a perfect fit for Grünenthal with our existing customer base and complementary product portfolio", says Gabriel Baertschi, CEO, Grünenthal. "The acquisition of Valinor Pharma strengthens our footprint in the United States, the most important growth market for Grünenthal."
“作为疼痛专家，Movantik与我们现有的客户群和补充产品组合完美契合”，Grunenthal首席执行官Gabriel Baertschi说：“Valinor Pharma的收购加强了我们在美国这个对Grunenthal最重要的增长市场的影响力。”
Marv Kelly, President of Grünenthal US, commented: "We are excited to welcome Valinor and expand our portfolio offering to pain specialists with Movantik."
Grunenthal美国总裁Marv Kelly评论道：“我们很高兴欢迎Valinor加入，并通过Movantik扩展我们面向疼痛专科医生的产品组合。”
Grünenthal acquired the product in Europe (branded Moventig outside of the U.S.) in 2023 as part of a joint venture with Kyowa-Kirin. The acquisition of Valinor makes Grünenthal the worldwide owner of the brand (ex-Canada).
Grunenthal在2023年通过与Kyowa-Kirin成立的Joint Venture获取了欧洲该产品的拥有权（在美国以外被称为Moventig）。收购Valinor使Grunenthal成为该品牌（除加拿大外）的全球拥有者。
With Movantik, Grünenthal continues to execute its strategy of acquiring established medicines to expand its portfolio and increase the company's profitability. Since 2017, Grünenthal has acquired several established medicines, including NebidoTM, the European rights to CrestorTM and NexiumTM, as well as the global rights to VimovoTM (excluding the U.S. and Japan), QutenzaTM and ZomigTM (excluding Japan). In 2023, Grünenthal established Grünenthal Meds, a joint venture with Kyowa Kirin International, which manages a portfolio of 13 brands primarily focused on pain management. Grünenthal has invested more than €2 billion in successful M&A transactions.
通过收购成熟药物来扩大其组合并增加公司的盈利能力是Grunenthal继续执行其策略的一部分。自2017年以来，Grunenthal已收购了多种成熟药物，包括NebidoTm，CrestorTm和NexiumTm的欧洲权利，以及VimovoTm（不包括美国和日本），QutenzaTm和ZomigTm（不包括日本）的全球权利。2023年，Grunenthal与Kyowa Kirin International成立了Joint Venture——Grunenthal Meds，管理着主要集中在疼痛管理领域的13个品牌组合。Grunenthal已经在成功的并购交易中投资超过20亿欧元。
About Grünenthal
有关Grunenthal
Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better, and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a world free of pain.
Grunenthal是疼痛管理和相关疾病的全球领导者。作为一家以科学为基础的全方位综合制药公司，我们长期以来一直致力于为全球患者带来创新治疗和最先进的技术。我们的宗旨是改变人们的生活，创新是我们的激情。我们将所有的活动和努力都集中在实现我们建立一个无痛的世界的愿景上。
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2023, Grünenthal employed around 4,400 people and achieved revenues of €1.8 billion.
Grunenthal总部位于德国亚琛，在欧洲、拉丁美洲和美国等27个国家设有分公司。我们的产品遍及约100个国家。2023年，Grunenthal雇用了约4400人，并实现了18亿欧元的收入。
More information: and Grünenthal Report 2023/24
更多信息: 和Grunenthal报告2023/24
Follow us on:
LinkedIn: Grunenthal Group
Instagram: grunenthal
请关注我们：
领英：Grunenthal Group
Instagram：grunenthal
For further information, please contact:
Florian Dieckmann, Head Global Corporate Affairs
[email protected]
如需更多信息，请联系：丹·努恩（Dan Noone）
Florian Dieckmann，全球企业事务负责人
[email protected]
SOURCE Grünenthal Group
来源：Grunenthal Group
